Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer
نویسندگان
چکیده
منابع مشابه
Oral etoposide for a 95-year-old patient with small cell lung cancer.
Leaking endotracheal tube cuffs are common problems in intensive care units. Repairing the leak is preferable to reintubation when patients have difficult airways, are hemodynamically unstable, or have been receiving high levels of PEEP Although endotracheal tube cuff leaks may result from a ruptured cuff balloon, the more common cause is an incompetent pilot balloon valve. Boussard et have rec...
متن کاملLow-dose oral etoposide monotherapy in adult Langerhans cell histiocytosis.
BACKGROUND The purpose of this study was to test the disease-controlling effect of low-dose oral etoposide monotherapy in adult-onset multisystem Langerhans cell histiocytosis. There are no previous reports of low-dose etoposide monotherapy for this condition. OBSERVATIONS A 27-year-old man with a 7-year history of multifocal chronic Langerhans cell histiocytosis presented with severe disabli...
متن کاملA phase II study of oral etoposide in elderly patients with small cell lung cancer.
Thirty five previously untreated patients with small cell lung cancer older than 70 years were treated with oral etoposide (800 mg/m2 over five consecutive days) every four weeks. Twenty two patients had extensive disease and 13 limited disease. The overall response rate was 71%. The median survival for patients with limited diseases was 16 (range 6-32) months and for patients with extensive di...
متن کاملOral treatment with etoposide in small cell lung cancer – dilemmas and solutions
BACKGROUND Etoposide is a chemotherapeutic agent, widely used for the treatment of various malignancies, including small cell lung cancer (SCLC), an aggressive disease with poor prognosis. Oral etoposide administration exhibits advantages for the quality of life of the patient as well as economic benefits. However, widespread use of oral etoposide is limited by incomplete and variable bioavaila...
متن کاملPaclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer.
We evaluated the feasibility and efficacy of combination paclitaxel (Taxol) (via 1-hour infusion), carboplatin (Paraplatin), and oral etoposide (VePesid) in the first-line treatment of patients with small-cell lung cancer. Between June 1993 and July 1996, 117 patients with small-cell lung cancer. were treated in two sequential phase II studies. The first 38 patients received a lower-dose regime...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 1993
ISSN: 0007-0920,1532-1827
DOI: 10.1038/bjc.1993.115